Rallybio Corporation (NASDAQ: RLYB) is a Healthcare company (Biotechnology) with a market capitalization of $82M. The Maz Rating grades it against the other companies in its sector.
Rallybio Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $15.29, Rallybio Corporation trades at 3.3x trailing earnings, 189.3x sales and 0.9x book value. Over the last twelve months it generated about $434853 of revenue and $25M of net income. It runs a gross margin of -742.9%, an operating margin of -4659.2% and a net margin of 6177.4%. It shows return on equity of 36.3%, return on invested capital of -20.8% and a free cash flow yield of 37.2%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 28.87. Over the past 52 weeks the share price ranged from $3.67 to $17.57, with a beta of -0.77.
Rallybio Corporation pays a dividend yielding 88.86%.
9 Wall Street analyst ratings cover the stock: 4 Buy and 5 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.